vs
Amphastar Pharmaceuticals, Inc.（AMPH）与APPFOLIO INC（APPF）财务数据对比。点击上方公司名可切换其他公司
APPFOLIO INC的季度营收约是Amphastar Pharmaceuticals, Inc.的1.4倍（$262.2M vs $183.1M），APPFOLIO INC净利率更高（16.2% vs 13.3%，领先2.8%），APPFOLIO INC同比增速更快（20.4% vs -1.8%），过去两年APPFOLIO INC的营收复合增速更高（15.3% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
AppFolio Inc.是一家2006年成立的美国企业，专注服务房地产行业，为客户提供软件即服务（SaaS）类应用产品及相关配套服务，助力房地产相关经营主体优化管理流程、提升运营效率。
AMPH vs APPF — 直观对比
营收规模更大
APPF
是对方的1.4倍
$183.1M
营收增速更快
APPF
高出22.3%
-1.8%
净利率更高
APPF
高出2.8%
13.3%
两年增速更快
APPF
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $262.2M |
| 净利润 | $24.4M | $42.4M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 19.4% |
| 净利率 | 13.3% | 16.2% |
| 营收同比 | -1.8% | 20.4% |
| 净利润同比 | -35.7% | 35.2% |
| 每股收益（稀释后） | $0.51 | $1.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHAPPF
| Q1 26 | — | $262.2M | ||
| Q4 25 | $183.1M | $248.2M | ||
| Q3 25 | $191.8M | $249.4M | ||
| Q2 25 | $174.4M | $235.6M | ||
| Q1 25 | $170.5M | $217.7M | ||
| Q4 24 | $186.5M | $203.7M | ||
| Q3 24 | $191.2M | $205.7M | ||
| Q2 24 | $182.4M | $197.4M |
净利润AMPHAPPF
| Q1 26 | — | $42.4M | ||
| Q4 25 | $24.4M | $39.9M | ||
| Q3 25 | $17.4M | $33.6M | ||
| Q2 25 | $31.0M | $36.0M | ||
| Q1 25 | $25.3M | $31.4M | ||
| Q4 24 | $38.0M | $102.7M | ||
| Q3 24 | $40.4M | $33.0M | ||
| Q2 24 | $37.9M | $29.7M |
毛利率AMPHAPPF
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
营业利润率AMPHAPPF
| Q1 26 | — | 19.4% | ||
| Q4 25 | 19.4% | 17.6% | ||
| Q3 25 | 13.2% | 14.1% | ||
| Q2 25 | 24.2% | 17.2% | ||
| Q1 25 | 21.9% | 15.5% | ||
| Q4 24 | 24.2% | 11.3% | ||
| Q3 24 | 29.8% | 20.7% | ||
| Q2 24 | 30.3% | 18.3% |
净利率AMPHAPPF
| Q1 26 | — | 16.2% | ||
| Q4 25 | 13.3% | 16.1% | ||
| Q3 25 | 9.0% | 13.5% | ||
| Q2 25 | 17.8% | 15.3% | ||
| Q1 25 | 14.8% | 14.4% | ||
| Q4 24 | 20.4% | 50.4% | ||
| Q3 24 | 21.1% | 16.0% | ||
| Q2 24 | 20.8% | 15.0% |
每股收益（稀释后）AMPHAPPF
| Q1 26 | — | $1.18 | ||
| Q4 25 | $0.51 | $1.10 | ||
| Q3 25 | $0.37 | $0.93 | ||
| Q2 25 | $0.64 | $0.99 | ||
| Q1 25 | $0.51 | $0.86 | ||
| Q4 24 | $0.74 | $2.79 | ||
| Q3 24 | $0.78 | $0.90 | ||
| Q2 24 | $0.73 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $147.4M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $470.2M |
| 总资产 | $1.6B | $580.6M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHAPPF
| Q1 26 | — | $147.4M | ||
| Q4 25 | $282.8M | $107.0M | ||
| Q3 25 | $276.2M | $76.1M | ||
| Q2 25 | $231.8M | $73.5M | ||
| Q1 25 | $236.9M | $56.9M | ||
| Q4 24 | $221.6M | $42.5M | ||
| Q3 24 | $250.5M | $62.4M | ||
| Q2 24 | $217.8M | $59.6M |
总债务AMPHAPPF
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHAPPF
| Q1 26 | — | $470.2M | ||
| Q4 25 | $788.8M | $542.6M | ||
| Q3 25 | $776.7M | $498.9M | ||
| Q2 25 | $757.5M | $455.6M | ||
| Q1 25 | $751.3M | $462.1M | ||
| Q4 24 | $732.3M | $519.3M | ||
| Q3 24 | $727.7M | $412.8M | ||
| Q2 24 | $713.3M | $371.4M |
总资产AMPHAPPF
| Q1 26 | — | $580.6M | ||
| Q4 25 | $1.6B | $689.0M | ||
| Q3 25 | $1.7B | $640.5M | ||
| Q2 25 | $1.6B | $567.4M | ||
| Q1 25 | $1.6B | $564.7M | ||
| Q4 24 | $1.6B | $626.7M | ||
| Q3 24 | $1.5B | $523.3M | ||
| Q2 24 | $1.5B | $479.3M |
负债/权益比AMPHAPPF
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $34.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | 0.81× |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHAPPF
| Q1 26 | — | $34.3M | ||
| Q4 25 | $32.9M | $65.0M | ||
| Q3 25 | $52.6M | $86.0M | ||
| Q2 25 | $35.6M | $52.6M | ||
| Q1 25 | $35.1M | $38.5M | ||
| Q4 24 | $29.0M | $36.6M | ||
| Q3 24 | $60.0M | $57.8M | ||
| Q2 24 | $69.1M | $50.9M |
自由现金流AMPHAPPF
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $63.7M | ||
| Q3 25 | $47.2M | $84.7M | ||
| Q2 25 | $25.0M | $52.4M | ||
| Q1 25 | $24.4M | $38.2M | ||
| Q4 24 | $16.6M | $36.4M | ||
| Q3 24 | $46.2M | $57.4M | ||
| Q2 24 | $63.1M | $50.8M |
自由现金流率AMPHAPPF
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 25.7% | ||
| Q3 25 | 24.6% | 34.0% | ||
| Q2 25 | 14.3% | 22.2% | ||
| Q1 25 | 14.3% | 17.6% | ||
| Q4 24 | 8.9% | 17.9% | ||
| Q3 24 | 24.1% | 27.9% | ||
| Q2 24 | 34.6% | 25.8% |
资本支出强度AMPHAPPF
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 0.5% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 6.3% | 0.1% | ||
| Q4 24 | 6.7% | 0.1% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 3.3% | 0.0% |
现金转化率AMPHAPPF
| Q1 26 | — | 0.81× | ||
| Q4 25 | 1.35× | 1.63× | ||
| Q3 25 | 3.03× | 2.56× | ||
| Q2 25 | 1.15× | 1.46× | ||
| Q1 25 | 1.39× | 1.23× | ||
| Q4 24 | 0.76× | 0.36× | ||
| Q3 24 | 1.48× | 1.75× | ||
| Q2 24 | 1.82× | 1.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APPF
| Value Added Services | $201.4M | 77% |
| Subscription Services | $58.2M | 22% |
